NFKB1 and chronic obstructive pulmonary disease: The results demonstrate that JPYF II reduced pulmonary inflammation via suppression of the NF-κB pathway and excessive oxidative stress, which indicated that it was the underlying mechanism of JPYF II in the treatment of COPD and provided a theoretical basis for future research and clinical application.